

Eric D Bateman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4820265/publications.pdf>

Version: 2024-02-01

141
papers

21,959
citations

16411

64
h-index

11030

137
g-index

142
all docs

142
docs citations

142
times ranked

14573
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to the correspondence: “Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma” Respiratory Medicine, 2022, 191, 106088.	1.3	0
2	Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020). Respiratory Medicine, 2022, 191, 106106.	1.3	0
3	Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. Respiratory Medicine, 2022, 191, 105991.	1.3	13
4	Short-acting β_2 -agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. European Respiratory Journal, 2022, 59, 2101402.	3.1	50
5	A Practical Guide to Implementing SMART in Asthma Management. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, S31-S38.	2.0	34
6	Global Initiative for Asthma Strategy 2021. Respirology, 2022, 27, 14-35.	1.3	31
7	Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. European Respiratory Journal, 2022, 59, 2102730.	3.1	218
8	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 17-35.	2.5	196
9	Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes. Archivos De Bronconeumologia, 2022, 58, 35-51.	0.4	31
10	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, S1-S18.	2.0	66
11	Reply to: Cause or consequence?. European Respiratory Journal, 2022, 59, 2200103.	3.1	1
12	Asthma management in low and middle income countries: case for change. European Respiratory Journal, 2022, 60, 2103179.	3.1	45
13	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	2.7	46
14	ARIA’s EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	2.7	57
15	Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respiratory Medicine, 2021, 9, 149-158.	5.2	46
16	Prevalence and Population-Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1353-1365.	2.5	52
17	Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. Drug Safety, 2021, 44, 467-478.	1.4	8
18	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	6.3	176

#	ARTICLE	IF	CITATIONS
19	Positioning As-needed Budesonide-Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2. <i>Annals of the American Thoracic Society</i> , 2021, 18, 2007-2017.	1.5	17
20	Chronic airflow obstruction and ambient particulate air pollution. <i>Thorax</i> , 2021, 76, 1236-1241.	2.7	7
21	Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3069-3077.e6.	2.0	22
22	Reply to "As-needed budesonide-formoterol for adolescents with mild asthma: importance of lung function". <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4179-4180.	2.0	0
23	<p></p>Transition from Restrictive to Obstructive Lung Function Impairment During Treatment and Follow-Up of Active Tuberculosis</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1039-1047.	0.9	25
24	What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?. <i>Respirology</i> , 2020, 25, 804-815.	1.3	29
25	GINA 2019: a fundamental change in asthma management. <i>European Respiratory Journal</i> , 2019, 53, 1901046.	3.1	277
26	The Global Initiative for Asthma (GINA): 25...years later. <i>European Respiratory Journal</i> , 2019, 54, 1900598.	3.1	174
27	Helsinki by nature: The Nature Step to Respiratory Health. <i>Clinical and Translational Allergy</i> , 2019, 9, 57.	1.4	36
28	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	1.4	87
29	Prevalence and Characteristics of Asthma- Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1143-1150.	1.5	32
30	Global Initiative for Asthma 2016-derived asthma control with fluticasone propionate and salmeterol. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 57-63.e2.	0.5	10
31	<p></p>Randomized dose-finding study of bafepenterol via dry powder inhaler in patients with COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 615-629.	0.9	8
32	Overdiagnosis of COPD in Subjects With Unobstructed Spirometry. <i>Chest</i> , 2019, 156, 277-288.	0.4	57
33	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	1.5	103
34	Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 489-495.	2.5	17
35	Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 589-596.e3.	2.0	69
36	Airflow Obstruction and Use of Solid Fuels for Cooking or Heating. <i>BOLD (Burden of Obstructive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	2.5	69

#	ARTICLE	IF	CITATIONS
37	Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 923-935.e9.	2.0	64
38	Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β_2 -agonists in patients with atopic asthma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1093-1106.	2.0	18
39	As-Needed Budesonide-Formoterol in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 379, 897-898.	13.9	11
40	Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 1865-1876.	13.9	453
41	As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 1877-1887.	13.9	368
42	Combined Analysis of Asthma Safety Trials of Long-Acting β_2 -Agonists. <i>New England Journal of Medicine</i> , 2018, 378, 2497-2505.	13.9	76
43	Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1171-1180.	2.5	26
44	The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given "as needed"™ in mild asthma: study protocols for two randomised controlled trials. <i>Trials</i> , 2017, 18, 12.	0.7	30
45	A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma. <i>Allergy and Asthma Proceedings</i> , 2017, 38, 157-164.	1.0	25
46	Fevipirant, an oral prostaglandin DP ₂ receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. <i>European Respiratory Journal</i> , 2017, 50, 1700670.	3.1	93
47	The paradoxes of asthma management: time for a new approach?. <i>European Respiratory Journal</i> , 2017, 50, 1701103.	3.1	130
48	Severity of Airflow Obstruction in Chronic Obstructive Pulmonary Disease (COPD): Proposal for a New Classification. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 469-475.	0.7	16
49	Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment. <i>BMC Pulmonary Medicine</i> , 2017, 17, 65.	0.8	6
50	Safety and tolerability of once-daily tiotropium Respimat Â® as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. <i>Respiratory Medicine</i> , 2016, 118, 102-111.	1.3	31
51	Integrated clinical management tools for respiratory diseases: lessons from PAL in sub-Saharan Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 429-429.	0.6	1
52	Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 441-450.e8.	1.5	133
53	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. <i>European Respiratory Journal</i> , 2016, 47, 1028-1033.	3.1	50
54	Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. <i>Lancet Respiratory Medicine</i> , 2016, 4, 781-796.	5.2	398

#	ARTICLE	IF	CITATIONS
55	Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses. <i>Respiratory Medicine</i> , 2016, 120, 91-100.	1.3	4
56	Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. <i>Respiratory Medicine</i> , 2016, 117, 198-206.	1.3	87
57	Comment on: "Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β_2 -Agonists". <i>Applied Health Economics and Health Policy</i> , 2016, 14, 117-118.	1.0	0
58	Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 142-149.e8.	1.5	49
59	Lung function defects in treated pulmonary tuberculosis patients. <i>European Respiratory Journal</i> , 2016, 47, 352-353.	3.1	5
60	Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD. <i>European Respiratory Journal</i> , 2016, 47, 651-654.	3.1	19
61	Asthma attacks: how can we reduce the risks?. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 14105.	1.1	4
62	Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and) <i>Tj ETQq0 0 0 rBT /Overlook 10 TF 5</i>		
63	Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. <i>Lancet Respiratory Medicine</i> , 2015, 3, 355-366.	5.2	937
64	Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1457-1464.e4.	1.5	88
65	Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD) <i>Tj ETQq1 1 0.784314 rgBT /Overlook 294</i>	3.1	294
66	The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?. <i>Lancet Respiratory Medicine</i> , 2015, 3, 719-728.	5.2	142
67	Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 37-44.	1.1	78
68	Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. <i>European Respiratory Journal</i> , 2015, 46, 1104-1112.	3.1	159
69	Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. <i>Lancet Respiratory Medicine</i> , 2015, 3, 367-376.	5.2	153
70	Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 914-922.	1.5	58
71	Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. <i>Journal of Asthma</i> , 2015, 52, 1073-1083.	0.9	35
72	A summary of the new GINA strategy: a roadmap to asthma control. <i>European Respiratory Journal</i> , 2015, 46, 622-639.	3.1	636

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of acclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 178.	0.8	156
74	Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. <i>Thorax</i> , 2014, 69, 312-319.	2.7	73
75	Treatment adherence in asthmatic patients: The last frontier?. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1269-1270.	1.5	10
76	Efficacy of Varenicline Combined With Nicotine Replacement Therapy vs Varenicline Alone for Smoking Cessation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 155.	3.8	135
77	Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 267-276.	5.2	149
78	Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. <i>European Journal of Health Economics</i> , 2014, 15, 69-82.	1.4	23
79	Efficacy and safety of fluticasone furoate 100 $\hat{\wedge}$ 1/4g once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial. <i>Respiratory Medicine</i> , 2014, 108, 41-49.	1.3	37
80	International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. <i>European Respiratory Journal</i> , 2014, 43, 343-373.	3.1	2,898
81	Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and povertyâ€™a BOLD analysis. <i>Thorax</i> , 2014, 69, 465-473.	2.7	190
82	Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. <i>European Respiratory Journal</i> , 2014, 44, 1156-1165.	3.1	60
83	Recent advances in COPD disease management with fixed-dose long-acting combination therapies. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 357-379.	1.0	30
84	Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. <i>European Respiratory Journal</i> , 2014, 43, 773-782.	3.1	72
85	Efficacy and safety of fluticasone furoate 100 $\hat{\wedge}$ 1/4g and 200 $\hat{\wedge}$ 1/4g once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 113.	0.8	22
86	Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. <i>Respiratory Research</i> , 2014, 15, 88.	1.4	19
87	Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. <i>Journal of Negative Results in BioMedicine</i> , 2014, 13, 9.	1.4	18
88	Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty: a BOLD analysisâ€™authorsâ€™ reply. <i>Thorax</i> , 2014, 69, 869.2-870.	2.7	9
89	Fluticasone Furoateâ€™Vilanterol 100-25 mcg Compared with Fluticasone Furoate 100 mcg in Asthma: A Randomized Trial. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 553-561.	2.0	40
90	QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014, 2, 48-60.	0.5	7

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol+fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. <i>Lancet Respiratory Medicine</i> , 2013, 1, 51-60.	5.2	279
92	A Systematic Review of the Association between Pulmonary Tuberculosis and the Development of Chronic Airflow Obstruction in Adults. <i>Respiration</i> , 2013, 86, 76-85.	1.2	116
93	Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2013, 26, 581-587.	1.1	35
94	Integrating real-life studies in the global therapeutic research framework. <i>Lancet Respiratory Medicine</i> , 2013, 1, e29-e30.	5.2	102
95	Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. <i>European Respiratory Journal</i> , 2013, 42, 1484-1494.	3.1	358
96	Efficacy and safety of high-dose ciclesonide for the treatment of severe asthma. <i>Expert Review of Respiratory Medicine</i> , 2013, 7, 339-348.	1.0	6
97	Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β_2 agonist vilanterol administered once daily for 52 weeks in patients 12 years old with asthma: a randomised trial. <i>Thorax</i> , 2013, 68, 513-520.		69
98	Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma. <i>Chest</i> , 2013, 144, 1222-1229.	0.4	86
99	Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. <i>European Respiratory Journal</i> , 2012, 40, 830-836.	3.1	168
100	Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. <i>Thorax</i> , 2012, 67, 35-41.	2.7	72
101	A guide to the translation of the Global Initiative for Asthma (GINA) strategy into improved care. <i>European Respiratory Journal</i> , 2012, 39, 1220-1229.	3.1	105
102	Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. <i>Lancet</i> , 2012, 380, 889-898.	6.3	243
103	Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy. <i>New England Journal of Medicine</i> , 2012, 367, 1198-1207.	13.9	578
104	Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. <i>Thorax</i> , 2012, 67, 781-788.	2.7	147
105	Dose effect of once-daily fluticasone furoate in persistent asthma: A randomized trial. <i>Respiratory Medicine</i> , 2012, 106, 642-650.	1.3	67
106	Global asthma prevalence in adults: findings from the cross-sectional world health survey. <i>BMC Public Health</i> , 2012, 12, 204.	1.2	1,106
107	Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 109, 353-358.e4.	0.5	47
108	Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD. <i>Clinical Respiratory Journal</i> , 2012, 6, 248-257.	0.6	3

#	ARTICLE	IF	CITATIONS
109	Roflumilast with long-acting β_2 -agonists for COPD: influence of exacerbation history. <i>European Respiratory Journal</i> , 2011, 38, 553-560.	3.1	117
110	Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 315-322.	1.5	185
111	Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. <i>Respiratory Research</i> , 2011, 12, 160.	1.4	42
112	Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. <i>Respiratory Research</i> , 2011, 12, 132.	1.4	42
113	Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. <i>Respiratory Research</i> , 2011, 12, 38.	1.4	58
114	COPD in Never Smokers. <i>Chest</i> , 2011, 139, 752-763.	0.4	444
115	Overall asthma control: The relationship between current control and future risk. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 600-608.e6.	1.5	219
116	Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. <i>International Journal of COPD</i> , 2010, 5, 197-208.	0.9	48
117	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 59-99.	2.5	1,591
118	Within-Subject Variability and Boosting of T-Cell Interferon- γ Responses after Tuberculin Skin Testing. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 49-58.	2.5	169
119	Alternative mechanisms for tiotropium. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 533-542.	1.1	109
120	Systems for the management of respiratory disease in primary care "an international series: South Africa. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2009, 18, 69-75.	2.5	8
121	Occupational allergy and asthma among salt water fish processing workers. <i>American Journal of Industrial Medicine</i> , 2008, 51, 899-910.	1.0	74
122	Meta-analysis: Effects of Adding Salmeterol to Inhaled Corticosteroids on Serious Asthma-Related Events. <i>Annals of Internal Medicine</i> , 2008, 149, 33.	2.0	97
123	Development of a South African integrated syndromic respiratory disease guideline for primary care. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2008, 17, 156-163.	2.5	30
124	Rate of Response of Individual Asthma Control Measures Varies and May Overestimate Asthma Control: An Analysis of the Goal Study. <i>Journal of Asthma</i> , 2007, 44, 667-673.	0.9	28
125	Improvement in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2007, 16, 155-161.	2.5	26
126	A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. <i>Respiratory Medicine</i> , 2007, 101, 1677-1686.	1.3	49

#	ARTICLE	IF	CITATIONS
127	Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma control study. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 1036-1042.	1.5	71
128	High Prevalence of Tuberculosis in Previously Treated Patients, Cape Town, South Africa. <i>Emerging Infectious Diseases</i> , 2007, 13, 1189-1194.	2.0	69
129	Efficacy and safety of roflumilast in the treatment of asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 96, 679-686.	0.5	82
130	Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 563-570.	1.5	84
131	Identifying "well-controlled" and "not well-controlled" asthma using the Asthma Control Questionnaire. <i>Respiratory Medicine</i> , 2006, 100, 616-621.	1.3	795
132	Ciclesonide Reduces the Need for Oral Steroid Use in Adult Patients With Severe, Persistent Asthma. <i>Chest</i> , 2006, 129, 1176-1187.	0.4	46
133	Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 129-136.	2.5	593
134	Roflumilast "an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. <i>Lancet, The</i> , 2005, 366, 563-571.	6.3	443
135	Can Guideline-defined Asthma Control Be Achieved?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 836-844.	2.5	1,489
136	Combination Therapy with Single Inhaler Budesonide/Formoterol Compared with High Dose of Fluticasone Propionate Alone in Patients with Moderate Persistent Asthma. <i>Treatments in Respiratory Medicine</i> , 2003, 2, 275-281.	1.4	69
137	A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol. <i>Chest</i> , 2002, 122, 47-55.	0.4	428
138	Inhaled Triamcinolone Acetonide HFA 450µg Twice Daily Compared with Beclomethasone Dipropionate CFC 500µg Twice Daily in Adults with Moderate Persistent Asthma. <i>Clinical Drug Investigation</i> , 2000, 20, 9-17.	1.1	1
139	Salmeterol/Fluticasone Propionate Combination. <i>Drugs</i> , 1999, 57, 941-943.	4.9	1
140	Silicosis among gemstone workers in South Africa: Tiger's-eye pneumoconiosis. <i>American Journal of Industrial Medicine</i> , 1991, 19, 205-213.	1.0	15
141	Lung Diseases in South Africa: An Overview. <i>Novartis Foundation Symposium</i> , 0, , 4-16.	1.2	5